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THE BATTLE AGAINST ANTIMICROBIAL
DRUG RESISTANCE: ANALYZING RECENT
DEVELOPMENTS AND THE NECESSITY FOR
MAJOR AGRICULTURAL REFORMS
NIKKI SANFORD*
INTRODUCTION
Antimicrobial drug resistance is currently a major public health,
environmental, and economic concern. When the effectiveness of current
drugs diminishes, the ability to treat diseases and contain outbreaks is
greatly reduced and healthcare costs rapidly increase.1
Over the past decade, several legislative proposals unsuccessfully
attempted to address the issue, and public interest groups continue to
pressure the government to take action.2 Most recently, the Second Cir-
cuit’s July 2014 ruling in Natural Resources Defense Council v. FDA re-
versed the District Court’s decision that the Food & Drug Administration
(“FDA”) is obligated to hold hearings to withdraw approval on certain
drugs found to promote antibiotic-resistant bacteria through its current
usage.3 In September 2014, President Obama signed an Executive Order
establishing the National Strategy on Combating Antibiotic-Resistant
Bacteria, and created a Task Force and Presidential Advisory Council on
the matter.4
This Note will argue that the Second Circuit erred in its decision
in NRDC v. FDA, and that while President Obama’s directive is a crucial,
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1 Antimicrobial resistance, WHO, available at http://www.who.int/mediacentre/factsheets
/fs194/en/ [https://perma.cc/TLY7-RRYF] (last updated Apr. 2014).
2 See infra Part I.C.
3 Natural Res. Def. Council v. FDA, 760 F.3d 151 (2d Cir. 2014) [hereinafter NRDC II].
4 CTRS. FOR DISEASE CONTROL & PREVENTION, NATIONAL STRATEGY FOR COMBATING ANTI-
BIOTIC-RESISTANT BACTERIA, (Sept. 2014), available at http://www.whitehouse.gov/sites
/default/files/docs/carb_national_strategy.pdf [https://perma.cc/RPP6-JTM2].
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productive step in addressing antimicrobial drug resistance, the main
strategy must focus on reforming current agricultural practices. To
accomplish this, there are three main areas that must be addressed. First,
scientific research must be increased to find efficient, alternative methods
to current feed practices. Second, the United States should look to inter-
national strategies and efforts for policy guidance. Third, public aware-
ness and knowledge must be raised to promote action.
I. BACKGROUND
A. Current Agricultural Overuse of Antibiotics
1. Historical Background of Antibiotic Use in Livestock
In the 1950s, scientists investigating dietary supplements for
poultry found that the fermentation byproducts of a new antibiotic, chlor-
tetracycline, increased the weight gain of chickens.5 Commercially, this
discovery became widely favored, since livestock could be brought to
market weight with less feed.6 Similar studies on swine and cattle were
conducted soon after and also found that those antibiotics accelerated
weight gain.7 Producers immediately began to realize significant eco-
nomic benefits.8
In addition to these commercial benefits, the overall health of
livestock seemed to benefit as well.9 The prevalence of common cattle and
poultry diseases decreased since entire herds could be treated in an
efficient manner.10
2. Current Usage
Recently, antibiotic usage has been increasing despite the growing
issue of drug resistance in humans.11 Antibiotic sales for livestock raised
5 R.H. Gustafson & R.E. Bowen, Antibiotic use in animal agriculture, 83 J. APPLIED
MICROBIOLOGY 531, 531–32 (1997).
6 Id.
7 Id.
8 Id. at 531.
9 Id.
10 Id. at 531–32.
11 Sabrina Tavernise, Antibiotics in Livestock: F.D.A. Finds Use Is Rising, N.Y. TIMES
(Oct. 2, 2014), http://www.nytimes.com/2014/10/03/science/antibiotics-in-livestock-fda
-finds-use-is-rising.html [https://perma.cc/TM4R-F8DA].
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for consumption rose 16% between 2009 and 2012.12 The FDA enacted
stricter usage regulations for cephalosporins, which are a type of drug
used in livestock, yet sales still increased by 37% between 2009 and
2012.13 The FDA’s 2012 Summary Report on Antimicrobials Sold or Dis-
tributed for Use in Food-Producing Animals states that overall, animal
feed additives account for 70% of all medically important antibiotics sold,
and drinking water additives account for 24%.14
Fluoroquinolone usage provides a clear example of the dangers of
resistance due to agricultural practice.15 Similarly, after campylobacter
strains became introduced in poultry feed, resistance developed at rates
correlated to their agricultural use.16 There had been no previous resis-
tance issues in individuals unless they had taken the drug or been to
countries where the drug was permitted in agricultural feed.17 Although
the FDA banned fluoroquinolone usage in 2005, this is a clear example
of threats posed by agricultural uses of antibiotics.18
B. Public Health & Environmental Impacts
1. Public Health Impacts
Antibiotic resistance severely affects public health,19 and is rec-
ognized by the World Health Organization (“WHO”) as a top global health
issue.20 Resistance occurs when bacteria evolve and adapt to their envi-
ronment.21 Antibiotics kill their targeted microorganisms, and bacterial
12 Id.
13 Id.
14 Summary Report, FDA, ANTIMICROBIALS SOLD OR DISTRIBUTED FOR USE IN FOOD-
PRODUCING ANIMALS 16 (2014).
15 Prescription for Trouble: Using Antibiotics to Fatten Livestock, UNION OF CONCERNED
SCIENTISTS, http://www.ucsusa.org/food_and_agriculture/our-failing-food-system/indus
trial-agriculture/prescription-for-trouble.html#.VMrYF3DF990 [https://perma.cc/5DAW
-69N7] (last visited Mar. 20, 2016).
16 Id.
17 Id.
18 Id.
19 WORLD HEALTH ORG., ANTIMICROBIAL RESISTANCE: GLOBAL REPORT ON SURVEILLANCE 3
(2014), available at http://www.who.int/drugresistance/documents/surveillancereport/en/
[https://perma.cc/D772-LCC5].
20 AM. SOC’Y OF AGRONOMY, Antibiotic resistance in agricultural environments: A call to
action, SCIENCEDAILY (Sept. 26, 2013), http://www.sciencedaily.com/releases/2013/09/1309
26142926.htm [https://perma.cc/GFA5-5NUP].
21 Antibiotic Use in Food-Producing Animals, CDC, http://www.cdc.gov/narms/animals
.html [https://perma.cc/AR8G-9DEY] (last updated Sept. 4, 2014).
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strains that are genetically resistant will survive and reproduce.22 The
population of these resistant bacterial strains can increase and infect
humans and animals.23 Those infected with resistant bacteria cannot be
treated by common antibiotics, and may be sick for a longer period of
time.24 The Center for Disease Control (“CDC”) estimates that antibiotic
resistant diseases infect over two million people each year, and kill at
least 23,000.25 The WHO states that resistance to certain strains of
common bacteria has spread to all regions of the world.26 This issue is a
current threat, which must be addressed before common infections be-
come untreatable.27
According to the CDC, the bacteria that pose the greatest threat
(categorized as “urgent”) are Clostridium difficile, Carbapenem-resistant
Enterobacteriaceae (“CRE”), and drug-resistant Neisseria gonorrhoeae.28
These three bacteria alone are estimated to cause over 500,000 cases
of human infections annually.29 Among the groups most at risk when
antibiotics become resistant are cancer chemotherapy patients, patients
undergoing surgery, individuals with rheumatoid arthritis, end-stage
renal disease dialysis patients, and organ and bone marrow transplant
recipients.30
2. Environmental Impacts
Antibiotics fed to livestock have a widespread impact that affects
crops, soil, water quality, and other living organisms.31 Treated livestock
22 Teshome H. Regassa et al., Antibiotic Use in Animal Production: Environmental Con-
cerns, HEARTLAND REG’L WATER COORDINATION INITIATIVE 5, available at http://extension
publications.unl.edu/assets/pdf/rp196.pdf [https://perma.cc/5XX9-E9R4] (last visited
Mar. 20, 2016).
23 Id.
24 Id.
25 Antibiotic Resistance Threats in the US, CDC, http://www.cdc.gov/features/AntibioticRe
sistanceThreats/index.html [https://perma.cc/WF3D-5AWQ] (last updated Sept. 16, 2013).
26 Antimicrobial resistance, supra note 1.
27 Id.
28 CTRS. FOR DISEASE CONTROL & PREVENTION, ANTIBIOTIC RESISTANCE THREATS IN THE
UNITED STATES 7 (2013), available at http://www.cdc.gov/drugresistance/pdf/ar-threats
-2013-508.pdf [https://perma.cc/5FMK-TG7K].
29 Id. at 15–16.
30 Id. at 27.
31 See Regassa, supra note 22; Matthew Cimitile, Crops absorb livestock antibiotics,
science shows, ENVTL. HEALTH NEWS (Jan. 6, 2009), http://www.environmentalhealthnews
.org/ehs/news/antibiotics-in-crops [https://perma.cc/E7EZ-H48D]; R. Pulicharla et al.,
2016] THE BATTLE AGAINST ANTIMICROBIAL DRUG RESISTANCE 993
excrete 90% of administered drugs in their urine and manure.32 Manure
is used as a fertilizer on over nine million hectares of U.S. land, and
plants readily absorb and accumulate the antibiotics in that soil.33 The
specific health implications of these reabsorbed antibiotics are not certain,
although plants “in direct contact with the soil,” (such as tubers and root
crops) may absorb antibiotics more easily, and crops that are not processed
before consumption (like cabbage and lettuce) will have greater quanti-
ties of antibiotics.34 A peer-reviewed scientific report from the University
of Nebraska states that the antibiotic toxicity risk to humans from manure-
grown crops is very low, yet the effects on microorganisms in the manure
and soil require additional research.35
Effects on native animals are another environmental concern. All
animals that graze fields with manure from antibiotic-fed livestock are po-
tential vectors for resistant bacteria.36 Resistance could then be transferred
from those animals to other organisms and spread to other ecosystems.37
Wastewater treatment plants are another source that often intro-
duces antibiotics into the environment.38 Sewage from both livestock and
antibiotic-tainted soil can spread antibiotic resistant bacteria through run-
off, spills, and soil leeching.39 Scientific data recognizing potential contam-
ination and waterborne bacterial pathogens due to runoff in recycled
water irrigation systems supports the concern for antibiotic resistance in
humans, resulting from these treatment plants and irrigation systems.40
C. Recent Legislative Attempts Addressing Antimicrobial Resistance
In light of these known consequences of drug resistance, several
legislative attempts have occurred in recent years to address the issue.
A persistent antibiotic partitioning and co-relation with metals in wastewater treatment
plant—Chlortetracycline, 2 J. ENVTL. CHEM. ENG’G 1596, 1596–97 (2014).
32 Cimitile, supra note 31.
33 Id.
34 Id.
35 Id.
36 Id.
37 Id.
38 Pulicharla et al., supra note 31, at 1596.
39 Nicole Fahrenfeld et al., Reclaimed Waters as a reservoir of antibiotic resistance genes:
distribution system and irrigation implications, 4 FRONTIERS IN MICROBIOLOGY 1, 8 (2013),
http://journal.frontiersin.org/Journal/10.3389/fmicb.2013.00130/full [https://perma.cc/C64C
-9LZ5].
40 Id.
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In March 2013, Congresswoman Louise Slaughter (New York)
introduced H.R. 1150: Preservation of Antibiotics for Medical Treatment
Act (“PAMTA”) to the House Committee on Energy and Commerce.41 The
related Senate bill, S. 1256: Preventing Antibiotic Resistance Act of 2013
(“PARA”), was introduced to the Senate Health, Education, Labor, and
Pensions Committee by Senator Dianne Feinstein (CA) in June 2013.42
PAMTA and PARA address several issues concerning animal
drugs and propose to (1) require new animal drugs applications to show
with reasonable certainty that no human harm will result due to any
nontherapeutic use of the drug; (2) prohibit the nontherapeutic use of
medically important antimicrobials in food-producing animals, unless the
reasonable certainty standard for no human harm is met; and (3) pro-
hibit using antimicrobials on food-producing animals for non-routine dis-
ease control, unless certain standards are met.43
However, neither of these bills have made it past their initial
introductions and committee referrals.44 Public interest groups and city
councils across the nation continue to urge Congress to act on PAMTA and
PARA.45 Petitions launched by Food Policy Action and Dr. Mark Hyman
in support of PAMTA and PARA have gathered over 130,000 signatures
as of August 2013.46 Food & Water Watch has assisted in local efforts,
and fourteen city councils have passed resolutions to prompt Congress to
pass the legislation.47
Another bill, H.R. 2285: Strategies to Address Antimicrobial Re-
sistance Act, was introduced to the House Energy and Commerce Commit-
tee by Congressman Jim Matheson (Utah) in June 2013.48 The related
Senate Bill with the same title was introduced by Senator Sherrod Brown
(Ohio) in April 2014.49 This legislation would enhance efforts to address
41 H.R. 1150, 113th Cong., 1st Sess. (2013); Antibiotic Resistance, Congresswoman Louise
M. Slaughter, https://louise.house.gov/issues/antibiotic-resistance [https://perma.cc/KKZ8
-KD94] (last visited Mar. 20, 2016) (discussing the rationale behind the Preservation of
Antibiotics for Medical Treatment Act).
42 S. 1256, 113th Cong., 1st Sess. (2013).
43 H.R. 1150.
44 See H.R. 1150; S. 1256.
45 Petitions Urge Congressional Action on Antibiotics Legislation, FOOD SAFETY NEWS
(Aug. 16, 2014), http://www.foodsafetynews.com/2014/08/petitions-attempt-to-prompt-con
gressional-action-to-antibiotics-legislation/#.VG0zY1XF9tI [https://perma.cc/5N8M-FHBY].
46 Id.
47 Id.
48 H.R. 2285, 113th Cong., 1st Sess. (2013).
49 S. 2236, 113th Cong., 2nd Sess. (2014).
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antimicrobial resistance by amending the Public Health Service Act to
require the Secretary of Health and Human Services to act in conjunction
with the FDA and CDC to revise a program to combat antimicrobial
resistance.50 But like PARA and PAMTA, these bills have stagnated and
have not gotten past their initial introductions to the Committee.51
D. Food and Drug Administration Actions
The FDA is making substantial efforts to take the lead and ad-
dress antimicrobial resistance issues.52 The Animal Drug and Animal
Generic Drug User Fee Reauthorization Act of 2013 allows the FDA to
gather information on the amounts and types of antimicrobial drugs sold
and distributed for use in food-producing animals,53 and to determine
appropriate approval policies and fees for new animal drugs.54 While this
requirement gathers quantitative data about the amount of antimicrobial
drugs in the market, the amount of drugs actually used is not known.55
The FDA has also compiled a “Guidance for Industry” report
(“GFI #213”), stating recommendations for the judicious use of animal
drugs in feed and drinking water for food-producing animals.56 Essen-
tially, this report suggests that industry (1) eliminate antimicrobial drug
use for enhancing animal growth or improving feed efficiency; (2) add
“scientifically-supported disease treatment, control, or prevention uses”;
50 H.R. 2285; S. 2236.
51 H.R. 2285; S. 2236.
52 See Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013,
S. 622, 113th Cong. (2013); FDA’s Strategy on Antimicrobial Resistance—Questions
and Answers, FDA, http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforce
ment/GuidanceforIndustry/ucm216939.htm [https://perma.cc/E24Q-YAW6] (last updated
Mar. 28, 2014) (discussing current FDA strategies and rationales for addressing anti-
microbial resistance).
53 S. 622, 113th Cong. § 105 (2013).
54 See generally S. 622.
55 Questions and Answers: Summary Report on Antimicrobials Sold or Distributed for
Use in Food-Producing Animals, FDA, http://www.fda.gov/ForIndustry/UserFees/Animal
DrugUserFeeActADUFA/ucm236149.htm [https://perma.cc/6P59-UVW2] (last updated
Oct. 2, 2014).
56 See generally Guidance for Industry #213, FDA, New Animal Drugs and New Animal
Drug Combination Products Administered in or on Medicated Feed or Drinking Water
of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning
Product Use Conditions with GFI #209 (Dec. 2013), available at http://www.fda.gov/down
loads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM
299624.pdf [https://perma.cc/W833-MFAJ].
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and (3) increase veterinary oversight by changing the marketing status of
drugs to either Veterinary Feed Directive (“VFD”) or prescription status.57
However, FDA “Guidance for Industry” reports are merely recommenda-
tions and nonbinding.58
E. CRDC v. FDA Lawsuit
1. Background
In 1972, an FDA Task Force studied the safety of subtherapeutic
antibiotic use in animal feed.59 The report stated that (1) subtherapeutic
uses of antibiotics favored antibiotic-resistant bacteria; (2) such use could
make treated animals hosts of resistant bacteria, and could transfer them
to humans; (3) the prevalence of resistant bacteria increased; and (4) resis-
tant bacteria had been found in meat products for human consumption.60
The Task Force also recommended withdrawing approval for subthera-
peutic uses of the drugs in animal feed, unless drug manufacturers could
show evidence regarding a drug’s safety and effectiveness.61
Then in 1977, the FDA’s Bureau of Veterinary Medicine issued
notice of opportunity hearings (“NOOH”) for two antibiotics commonly
used subtherapeutically in animal feed: penicillin and tetracyclines.62
These hearings would address the “safety and effectiveness” of these two
medicines on humans, since manufacturers had “failed to resolve the basic
safety questions [concerning their] subtherapeutic use” in animal feed.63
The formal withdrawal hearings to remove these antibiotics from
livestock feed were delayed by a House Appropriations Committee report,
which suggested that the National Academy of Sciences (“NAS”) should
first complete their pending research on the matter.64 The NAS studies ul-
timately found that the “subtherapeutic use of antimicrobials does increase
57 See FDA’s Strategy on Antimicrobial Resistance—Questions and Answers, supra note 52;
Guidance for Industry #213, supra note 56; Phasing Out Certain Antibiotic Use in Farm
Animals, FDA, http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm378100.htm#vol
untary [https://perma.cc/GNW9-WMHN] (last updated Dec. 13, 2013) (detailing the plan
and rationale behind the voluntary phase out of certain drugs used in animal feed).
58 Guidance for Industry #213, supra note 56.
59 NRDC II, 760 F.3d at 153.
60 Id. at 154.
61 Id.
62 Id.
63 Id.
64 See id.; see also H.R. Rep No. 95-1290, at 99 (1996).
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the prevalence of resistance” among the several strands of bacteria ob-
served, but more research on the matter should be conducted.65
Over the next couple decades, studies by government agencies and
independent organizations examined the connection between resistant
bacteria from food animals to humans.66 While evidence strongly indicated
that the subtherapeutic and therapeutic uses of antimicrobials are a
potential human health hazard, a “definitive direct link” had not been
established.67 Furthermore, the WHO recommended eliminating the ani-
mal use of any subtherapeutic antibiotics that are prescribed for human
use.68 Despite this body of information and multiple petitions from public-
interest groups, the FDA continued to delay the hearings proposed in 1977,
and they still have yet to be held.69
2. District Court Ruling—“NRDC I” (2011)
The National Resources Defense Council (“NRDC”), Center for
Science in the Public Interest (“CSPI”), Food Animal Concerns Trust
(“FACT”), Public Citizen, and Union of Concerned Scientists (“UCS”)
formed a coalition in 2011 attempting to compel hearing action regarding
penicillin and tetracycline use in animal feed.70 They brought the current
suit under two separate claims.71
First, the plaintiffs claimed that the FDA is required under 21
U.S.C. § 360b(e)(1) to hold the proposed hearings from the 1977 NOOHs.72
65 NRDC II, 760 F.3d at 154–55.
66 Id. at 155.
67 Id.
68 Id.
69 Id. at 155–56.
70 Courtney Hamilton, Superbug Suit: Groups Sue FDA Over Risky Use of Human Anti-
biotics in Animal Feed, NATURAL RES. DEFENSE COUNCIL, http://www.nrdc.org/media/2011
/110525.asp [https://perma.cc/9LDR-FF8N] (last visited Mar. 20, 2016).
71 NRDC II, 760 F.3d at 156.
72 Id.; see 21 U.S.C. § 360b(e)(1):
The Secretary shall, after due notice and opportunity for hearing to the
applicant, issue an order withdrawing approval of an application filed
pursuant to subsection (b) of this section with respect to any new ani-
mal drug if the Secretary finds—
(A) that experience or scientific data show that such drug is unsafe
for use under the conditions of use upon the basis of which the
application was approved or the condition of use authorized
under subsection (a)(4)(A) of this section;
(B) that new evidence not contained in such application or not
available to the Secretary until after such application was
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Second, they claimed that the FDA unreasonably failed to respond to
citizen petitions supporting the hearings.73
The FDA responded by formally withdrawing the 1977 NOOHs,
denying the citizen petitions, and stating that alternative strategies to
combat negative consequences of subtherapeutic antibiotic use would be
explored, instead of holding costly, lengthy withdrawal proceedings.74 The
plaintiffs then amended their complaint, claiming that the NOOH with-
drawals were “arbitrary and capricious.”75
The District Court granted summary judgment to the plaintiffs
on both claims.76 The court found that the 1977 NOOH showed that the
drugs were not safe, and the FDA is required to institute withdrawal pro-
ceedings unless drug manufacturers could show the required safety and
effectiveness for each drug.77 The FDA subsequently appealed the District
Court’s ruling, and the Second Circuit reviewed the decision de novo.78
3. Second Circuit Ruling—“NRDC II” (2014)
In July 2014, the Second Circuit reversed the District Court’s
decision, finding for the government on both claims.79 As to the first claim,
the court held that 21 U.S.C. § 360b(e)(1) should be interpreted that if,
after a hearing, a drug is shown to be unsafe, then the FDA must with-
draw the drug’s approval.80 This contrasts with the NRDC’s view that after
the agency’s internal finding that a drug is unsafe, it must hold a hearing,
approved, or tests by new methods, or tests by methods not
deemed reasonably applicable when such application was ap-
proved, evaluated together with the evidence available to the
Secretary when the application was approved, shows that such
drug is not shown to be safe for use under the conditions of use
upon the basis of which the application was approved or that
subparagraph (i) of paragraph (1) of subsection (d) of this
section applies to such drug.
73 NRDC II, 760 F.3d at 156.
74 Id. at 156–57.
75 Id. at 157. See 5 U.S.C. § 706(2) (2014) (indicating the “Scope of Review” for the arbitrary
and capricious standard being contested).
76 See Natural Res. Def. Council v. FDA, 884 F. Supp.2d 127 (S.D.N.Y. 2012) [hereinafter
NRDC I].
77 NRDC II, 760 F.3d at 157.
78 Id.
79 Id. at 153.
80 Id. at 158.
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report new findings from further investigation, and withdraw the order.81
Although the court admitted that the statutory language is ambiguous
as to the sequential order of hearing, finding, and withdrawal process,
the FDA’s interpretation seems more plausible, since the statute does not
explicitly state that two findings (before and after hearing notice) must
be reported, or that the withdrawal process could be initiated prehearing.82
Regarding the second claim, the court found that the denial of the
citizens’ petitions and withdrawal of the 1977 NOOHs were not “arbitrary
and capricious.”83 The court reasoned that the decision to initiate or ter-
minate hearings potentially leading to a drug’s withdrawal “is a discre-
tionary determination left to the prudent choice of the FDA.”84 The court
also pointed out that the lack of direct scientific evidence that penicillin
and tetracycline are “inherently dangerous” to humans,85 and that these
types of administrative decisions are typically deferred to the agency.86
Furthermore, because the FDA has implemented a strategy to combat
negative effects of subtherapeutic antibiotic use in animals, alternate reg-
ulatory mechanisms are in place to address the issue.87
F. Executive Order—Combating Antibiotic Resistant Bacteria
In December 2013, President Obama issued a directive to the Na-
tional Security Council (“NSC”) and the Office of Science and Technology
Policy (“OSTP”) to investigate current trends of antibiotic resistance and to
81 Id. at 159.
82 Id. at 159–61.
83 NRDC II, 760 F.3d at 153.
84 Id. at 175.
85 Id.
86 Id. at 174–75 (quoting New York Pub. Int. Research Group v. Whitman, 321 F.3d 316,
331 (quoting 42 U.S.C. 7661a(i)(1))):
Rejecting the view that the EPA was required to issue a notice of
deficiency whenever it found defects in a state permitting program,
we noted that ‘Congress could have fashioned a regime under which,
for example, an interested party could initiate the process leading to
a determination of whether “a permitting authority is adequately
administering and enforcing a program,” ’ but that by referring to a
“determination” on the part of the agency, Congress left it to the dis-
cretion of the EPA Administrator whether and when to initiate enforce-
ment proceedings.
87 Id. at 193–94; Guidance for Industry #213, supra note 56 (stating the FDA’s strategy
of asking drug manufacturers for voluntary compliance in relabeling drugs to reduce and
eliminate subtherapeutic uses in animals).
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create a plan to combat resistance.88 They established a policy committee
comprised of representatives from multiple federal agencies, including:
Department of Health and Human Services, Department of Agriculture, the
Environmental Protection Agency, and Department of Defense to review
recent efforts and goals.89 Thus, these efforts led to the development of
the National Strategy for Combating Antibiotic-Resistant Bacteria.90
President Obama signed an Executive Order titled “Combating
Antibiotic-Resistant Bacteria” on September 18, 2014.91 This established
the National Strategy for Combating Antibiotic-Resistant Bacteria, a Task
Force and Presidential Advisory Council, and plans to release a National
Action Plan and its implementation plans.92 The President’s Council of
Advisers on Science and Technology also released their “Report to the
President on Combating Antibiotic Resistance.”93
1. National Strategy for Combating Antibiotic-Resistant Bacteria
The five main goals of the National Strategy are to:
a. Slow the development of resistant bacteria and
prevent the spread of resistant infections.
b. Strengthen national one-health surveillance efforts
to combat resistance.
c. Advance development and use of rapid and innova-
tive diagnostic tests for identification and charac-
terization of resistant bacteria.
d. Accelerate basic and applied research and develop-
ment for new antibiotics, other therapeutics, and
vaccines.
88 NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA, supra note 4,
at 6.
89 Id.
90 Id.
91 See Exec. Order 13,676, 3 C.F.R. 13,676 (2014), available at https://www.whitehouse
.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria
[https://perma.cc/TJP3-RZ8H].
92 Id.
93 See PRESIDENT’S COUNCIL OF ADVISORS ON SCI. & TECH., REPORT TO THE PRESIDENT ON
COMBATING ANTIBIOTIC RESISTANCE, (Sept. 2014), available at http://www.whitehouse.gov
/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf [https://perma
.cc/9BNH-B9VR].
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e. Improve international collaboration and capacities
for antibiotic resistance prevention, surveillance,
control, and antibiotic research and development.94
These goals are informed by specific information on multiple
strains of bacteria that are currently classified by the CDC as “Urgent,”
“Serious,” or “Of Concern” in the United States.95 By 2020, the National
Strategy aims to drastically reduce the incidence of infection due to
“Urgent” and “Serious” bacterial threats as well.96
Furthermore, the Task Force established from the Executive Order
was supposed to report the five-year National Action Plan by February 15,
2015.97 This report will obtain input from the President’s Council of Ad-
visors on Science and Technology (“PCAST”) and the Secretaries of Health
and Human Services, Agriculture, and Defense to develop detailed steps
and strategies to achieve National Targets.98
2. PCAST Report to the President on Combating
Antibiotic Resistance
Three main focus areas are identified in this report as necessary
to combat the antibiotic-resistance threat:
1. Improving surveillance on the rise of antibiotic-
resistant bacteria;
2. Increasing the longevity of current antibiotics; and
3. Increasing the rate at which new antibiotics as well
as other inventions are discovered and developed.99
Eight recommendations are then set forth as guidelines to accom-
plish goals in these focus areas:
1. Ensure strong federal leadership;
2. Implement effective surveillance and response for
antibiotic resistance;
94 NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA, supra note 4,
at 5.
95 Id. at 25–28.
96 Id. at 33.
97 Exec. Order 13,676, supra note 91, § 3(c).
98 NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA, supra note 4,
at 1, 24.
99 PRESIDENT’S COUNCIL OF ADVISORS ON SCI. & TECH., supra note 93, at 1–2.
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3. Expand fundamental research to develop alterna-
tives to antibiotics in agriculture;
4. Develop a new infrastructure and regulatory
schemes to support clinical trials to develop new
antibiotics;
5. Significantly increase government-supported eco-
nomic incentives for developing urgently needed
antibiotics;
6. Improve stewardship of existing antibiotics in
health care;
7. Limit the use of antibiotics in animal agriculture;
and
8. Ensure effective international coordination.100
II. PROBLEMS AND/OR NEW DEVELOPMENTS
A. Main Issues
Both the NRDC decision and the National Strategy fail to take
into account the driving force behind the development of antibiotic-
resistant bacteria: agricultural practices. Over 70% of all the antibiotics
used in the United States goes to healthy livestock.101 These drugs are
not used for medicinal purposes, but to enhance these animals’ size and
weight and increase factory farm profits for companies in the agriculture
industry.102 These practices have an alarming effect on not only the rate
at which certain antibiotics are becoming ineffective, but on the environ-
ment as well. Water sources, native species, and public health are all
being adversely affected,103 and therefore, altering current industrial
practices is the most direct way to counter these current effects.
III. PROBLEMS WITH THE NRDC V. FDA DECISION
The NRDC v. FDA decision gives the FDA great discretion in de-
termining whether to hold proceedings concerning drugs used on animals,
and whether to hold hearings over drugs with serious safety concerns.104
100 Id. at 5–7.
101 UNION OF CONCERNED SCIENTISTS, supra note 15.
102 Id.
103 AM. SOC’Y OF AGRONOMY, supra note 20.
104 Diana R.H. Winters, Antibiotics in animal feed and thin statutory interpretation:
NRDC v. EPA, HARV. L: BILL OF HEALTH (July 25, 2014), http://blogs.law.harvard.edu/bill
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This decision contradicts statutory mandates and is counterproductive in
responding to scientific discoveries on the effects and implications of
animal drug usage because “the decision lets the FDA ‘openly declare that
a particular animal drug is unsafe, but then refuse to withdraw approval,’
and ‘effectively ignore’ challenges to that policy.”105
A. Statutory Interpretation
One issue with the NRDC v. FDA decision lies with statutory
interpretation—whether the FDA was required by 21 U.S.C. § 360b(e)(1)
to hold the withdrawal hearings once it found that the two drugs’ usage
was questionable.106 Under the majority’s reading of the statute, the FDA’s
discretion is so great that they may never be required to pursue formal
withdrawal proceedings for a drug, despite compelling safety concerns.107
Looking to other statutes of the Food, Drug, and Cosmetics Act,
along with previous cases, the FDA should have been compelled to hold
the withdrawal hearings.108 For example, United States v. Gypsum holds
that after the FDA’s preliminary finding of a drug to be unsafe, the drug’s
sponsor must be given a hearing to rebut that finding.109 In the current
case, clearly no hearing was held.
In NRDC’s dissent, Judge Katzmann dispels the FDA’s argument
that under Heckler v. Chaney, the FDA’s decision on the NOOHs is not
judicially reviewable.110 Although courts typically defer to the discretion
of agencies about administrative decisions, a practice supported by the
holding in Heckler, here § 360b(e)(1)(B) requires the FDA to hold the
hearings.111 That decision is not up to the FDA’s discretion, since it re-
quires the FDA “to commence withdrawal proceedings when the agency
finds that a particular drug is not shown to be safe.”112
ofhealth/2014/07/25/antibiotics-in-animal-feed-and-thin-statutory-interpretation-nrdc-v
-epa/ [https://perma.cc/J8TB-8BVX].
105 Jonathan Stempel, U.S. court upholds FDA animal feed policy despite health concern,
REUTERS, July 24, 2014, http://uk.reuters.com/article/2014/07/24/us-usa-fda-animalfeed
-decision-idUKKBN0FT2A220140724 [https://perma.cc/63MU-ZYCD].
106 NRDC II, 760 F.3d at 174; see 21 U.S.C. § 360b(e)(1).
107 NRDC II, 760 F.3d at 177.
108 See 21 U.S.C. §§ 355, 360b(c)–(d) (2014).
109 U.S. v. Gypsum, 438 U.S. 422 (1978).
110 NRDC II, 760 F.3d at 186.
111 Id. at 187.
112 Id.
1004 WM. & MARY ENVTL. L. & POL’Y REV. [Vol. 40:989
B. Arbitrary and Capricious Inaction
Under Massachusetts v. EPA, “arbitrary and capricious” actions
are done for reasons “divorced from the statutory text.”113 This situation
is very similar to Massachusetts v. EPA in that both statutes in question
require mandatory action following a discretionary finding, and the
agency’s belief that action would require too much time and resources to
be justified.114 But, while the Supreme Court rejected those arguments
in Massachusetts v. EPA, the Second Circuit accepted them in NRDC v.
FDA.115 Because the FDA recognized valid human health concerns about
the drugs’ use in livestock, and failed to take the proper, statutorily man-
dated measures to address those concerns, the FDA’s decision should be
considered arbitrary and capricious.116
IV. PROBLEMS WITH THE NATIONAL STRATEGY
The Five-Step National Strategy is a significant development and
provides a solid starting point in addressing drug resistance,117 in con-
trast to failed legislative attempts.118 Promoting scientific research regard-
ing improved diagnostic testing, pharmaceutical developments, prevention,
and surveillance on antibiotic resistance are among the Strategy’s great-
est assets.119
However, the main issue with the White House’s National Strategy
report is that it does not directly address antibiotic usage in agriculture.120
Although the fourth step of the Strategy (accelerating research and de-
velopment) states that “alternatives to antibiotics are also needed in agri-
culture and veterinary medicine,” reducing current agricultural antibiotic
usage is not mentioned.121
113 Id. at 190 (quoting Mass. v. EPA, 549 U.S. 497, 532–33 (2007)).
114 Id. at 191.
115 Id.
116 NRDC II, 760 F.3d at 191.
117 See NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA, supra
note 4, at 1, 24.
118 See infra Part I.C.
119 Id.
120 See generally NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA,
supra note 4.
121 Id. at 2.
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V. RECENT DEVELOPMENTS AND INCREASED FUNDING
In January 2015, the White House released a Fact Sheet that
outlines the new federal efforts that will be taken to combat antibiotic
resistance.122 The Fiscal Year 2016 budget allocates over $1.2 billion in
funding to improve risk assessment, surveillance, reporting capabilities,
stewardship, and research innovation in the health and agricultural
industries.123 These goals nearly double the amount of federal funding in
past years124 and are a significant improvement to recent efforts.
The three proposed agricultural changes are (1) invest in basic
life sciences research; (2) intensify research and development of new
therapeutics and vaccines; and (3) develop alternatives to antibiotics
in agriculture.125
While these goals are likely to both reduce infection rates and
resistance rates if successfully implemented in the agricultural sector,
there is no certainty whether the industry will even adopt these potential
alternatives. This Fact Sheet and its funding goals raise similar concerns
to those that the National Strategy raises.126 Improvements to the agri-
cultural sectors are recognized,127 but no proposals are announced that
would substantively affect current practices and policies.
VI. AGRICULTURAL REFORMS AND SOLUTIONS
The most crucial step in developing an effective strategy to combat
antimicrobial drug resistance is directly addressing its overuse in agri-
culture. Since livestock consumes the greatest quantities of antibiotics,128
at a minimum, the usage of antibiotics in healthy livestock must be elim-
inated or greatly reduced.129
122 Fact Sheet: 2016 Budget Proposes Historic Investment to Combat Antibiotic-Resistant
Bacteria to Protect Public Health, THE WHITE HOUSE (Jan. 27, 2015), http://www.white
house.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes
-historic-investment-combat-a [https://perma.cc/2S6Z-TFJJ].
123 Id.
124 Id.
125 Id.
126 See generally id.
127 See generally id.
128 FDA, supra note 14.
129 See, e.g., Sharon Levy, Reduced Antibiotic Use in Livestock: How Denmark Tackled
Resistance, ENVTL. HEALTH PERSPECTIVES, June 1, 2014, http://ehp.niehs.nih.gov/122-a
160/?utm_source=rss&utm_medium=rss&utm_campaign=122-a160 [https://perma.cc/SK9Z
-GC7J].
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A. Scientific Strategies
Any plan to solve the growing issue of antibiotic drug resistance
will require scientific research to study, analyze, and assess the current
state of threats, as well as the effectiveness of potential strategies. Current
proposals to combat resistance recognize this necessity130 but do not do
enough to lay out a concrete action plan.
Focusing on the agricultural industry, research into effective,
healthy animal husbandry practices is an essential starting point.131 Op-
timizing livestock nutrition and maintaining lower animal densities are
necessary to relieve some dependence on antibiotics.132 Developing cost-
efficient vaccines to immunize farm animals and fish would help as well.133
In Norway, for example, salmon vaccines reduced antimicrobial use by
99% between 1987–2007, and fish production increased from 350,000–
850,000 tons.134 Similar success may reasonably be expected in the United
States if functional, economically efficient vaccines are developed.
Researching alternatives to antibiotics and the effects of currently
used alternatives is another useful strategy that can be used to combat
resistance. Certain metals like copper, zinc, and arsenic are often used as
alternatives,135 however, scientific studies have shown that these replace-
ments may be exacerbating the problem, since manure can introduce these
elements into water systems and soil.136
130 See generally NATIONAL STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA,
supra note 4; Fact Sheet: 2016 Budget Proposes Historic Investment to Combat Antibiotic-
Resistant Bacteria to Protect Public Health, supra note 122.
131 See AVMA Strategy Regarding Antimicrobial-Resistant Bacteria, AM. VETERINARY MED.
ASS’N, https://www.avma.org/KB/Policies/Pages/AVMA-Strategy-Regarding-Antimicrobial
-Resistant-Bacteria.aspx [https://perma.cc/4YRW-PTLZ] (last visited Mar. 20, 2016) (dis-
cussing the need for a science-based strategy to improve animal welfare, public health, and
public education regarding antimicrobial resistance).
132 Carol Potera, Germ Warfare? Strategies for Reducing the Spread of Antibiotic Resistance,
121 ENVTL. HEALTH PERSPECTIVES 255 (Aug. 1, 2013), http://ehp.niehs.nih.gov/121-a255/
[https://perma.cc/R8BH-ZH97].
133 Id.
134 Id.
135 Amy Pruden et al., Management Options for Reducing the Release of Antibiotics and
Antibiotic Resistance Genes to the Environment, 121 ENVTL. HEALTH PERSPECTIVES 878,
879–80 (2013); see Nanthi Bolan et al., Distribution and bioavailability of trace elements
in livestock and poultry manure by-products, 34 CRITICAL REVS. IN ENVTL. SCI. & TECH.
291 (2004) (discussing the health and environmental effects of using trace elements in
livestock feed).
136 Id.
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Thus, effective sanitation and waste management practices are
crucial to reducing the environmental effects that antibiotics cause. Devel-
oping strategies to manage, contain, and treat antibiotic-resistance genes
in manure will be the first step for improvement.137 Research studies
have found that composting waste can eliminate 50–70% of antibiotics,138
and treatment of manure can reduce antibiotic-resistant genes up to one
hundredfold, depending on the bacterial strain.139 Scientific research
needs to continue to develop ways to increase these kinds of beneficial
findings, and efforts to implement efficient waste-management strategies
must be increased.
B. Adopt Strategies Used Internationally
By looking internationally, especially at practices in Europe, the
United States could acquire some guidance as to best practices and poten-
tial strategies. The European Commission’s Action Plan against antimi-
crobial resistance proposes twelve specific steps, along with key actions to
combat resistance.140 Among these steps is the directive to “strengthen
EU law on veterinary medicines and on medicated feed.”141 Furthermore,
the European Food Safety Authority works closely with the European
Centre for Disease Prevention and Control (“ECDC”) and the European
Medicines Agency (“EMA”).142 The United States should focus on increasing
137 Pruden et al., supra note 135, at 880–81.
138 Id. (citing Ranjana Sharma et al., Selected antimicrobial resistance during composting
of manure from cattle administered sub-therapeutic antimicrobials, 38 J. ENVTL. QUALITY
567 (2009); Heather Storteboom et al., Tracking antibiotic resistance genes in the South
Platte River basin using molecular signatures of urban, agricultural, and pristine sources,
44 ENVTL. SCI. & TECH. 7397 (2007); L. Wang et al., Persistence of resistance to erythromycin
and tetracycline in swine manure during simulated composting and lagoon treatments, 63
MICROBIAL ECOLOGY 32 (2012); Wu et al., Abundance and diversity of tetracycline resis-
tance genes in soils adjacent to representative swine feedlots in China, 44 ENVTL. SCI. &
TECH. 6933 (2010)).
139 Pruden et al., supra note 135, at 880–81 (citing Storteboom, 44 ENVTL. SCI. & TECH. 7397).
140 Press Release, European Commission, Action Plan against antimicrobial resistance:
Commission unveils 12 concrete actions for the next five years (Nov. 17, 2011), available
at http://europa.eu/rapid/press-release_IP-11-1359_en.htm?locale=en [https://perma.cc
/DNG2-7CFP]; see also Antimicrobial Drug Resistance, EUROPEAN COMMISSION, http://ec
.europa.eu/research/health/infectious-diseases/antimicrobial-drug-resistance/index_en
.html [https://perma.cc/T43N-3FRC] (highlighting the European Union’s main research
and policy goals to deal with antimicrobial drug resistance).
141 Id.
142 Antimicrobial Resistance, EUR. FOOD SAFETY AUTH., http://www.efsa.europa.eu/en/top
ics/topic/amr.htm [https://perma.cc/XPC9-EBUN] (last updated Jan. 30, 2015).
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and improving collaboration between its federal food and public health
agencies, as well as exploring legislative strategies to reduce unnecessary
antibiotic use.
1. Denmark Case Study
To accomplish this, similar strategies to the ones successfully
used in Denmark could be effective.143 In 1995, Denmark became the first
country in Europe to ban the use of avoparcin (a drug commonly used as
a growth promoter for poultry), after studies demonstrated an increase
in vancomycin-resistant enterococci (“VRE”) from its use in livestock.144
Then in 1999, Denmark banned all nontherapeutic antibiotic use in
pork.145 Within two years, this policy resulted in a significant decline in
VRE in the fecal flora of both humans and food animals.146
Most notable, however, is that although antibiotic use in pigs
declined over 50% between 1992–2008, the pork industry’s production of
weaning pigs increased from 18.4 million to 27.1 million.147 While there
was a short term of increased pig mortality following the ban of avoparcin,
those levels decreased back to rates seen in 1992.148
A key factor in Denmark’s success is its monitoring of antibiotic
sales and usage before implementing the usage ban.149 By fostering coop-
eration and collaboration between the agricultural industry, scientists,
and the government, the transition to eliminating avoparcin usage became
practicable and more organized.150 These same strategies could be applied
in the United States, by targeting the drugs affecting bacterial strains
that are the greatest threat to public health.
Ultimately, a unified global effort is the most ideal way to best
combat drug resistance most effectively. Doing so would require collective
economic and legal mechanisms on behalf of each participating country.151
A WHO Bulletin addresses this idea, and points out that nations must
143 Levy, supra note 129.
144 Id.
145 Id.
146 Id.
147 Id.
148 Id.
149 Levy, supra note 129.
150 Id.
151 Richard D. Smith & Joanna Coast, Antimicrobial resistance: a global response, 80 BUL-
LETIN OF THE WHO 126, 126–27 (2002).
2016] THE BATTLE AGAINST ANTIMICROBIAL DRUG RESISTANCE 1009
“perceive a net benefit, often in economic terms” if the practical, rational
use of antimicrobials, is to occur.152
VII. INCREASE PUBLIC AWARENESS
Raising awareness of the health and environmental concerns of
antibiotic resistance could promote action and cooperation by government
and private industry. While the CDC releases an annual report highlight-
ing current threats,153 more can and should be done. The FDA at least rec-
ognizes this, as shown through the creation of a task force to address
resistance, and the actions of its members to raise public knowledge.154
The Infectious Diseases Society of America (“IDSA”) has made a
strong effort to raise awareness by working with Congress, the FDA, Na-
tional Institutes of Health, and other agencies and industry leaders to
consider research proposals and potential actions that the medical com-
munity can take.155 Many groups, including the WHO, have noted that
raising public awareness is crucial to tackling the many facets of anti-
microbial resistance.156 Efforts to do so must be continued in order to en-
courage political, scientific, and legal action in a timely manner.
CONCLUSION
Antimicrobial drug resistance is a growing concern that will
continue to damage public health and the environment. The driving force
behind the increased rates of drug resistance is the result of antibiotics’
extensive use in agricultural practices.157 The majority of drugs used in
livestock are not medically necessary, and questions about their negative
health impacts in humans have been raised.158
152 Id.
153 See Antibiotic Resistance Threats in the US, supra note 25.
154 Antimicrobial Resistance, FDA, http://www.fda.gov/NewsEvents/PublicHealthFocus
/ucm235649.htm [https://perma.cc/QJB3-E9ZP] (last updated Sept. 26, 2012).
155 HELEN W. BOUCHER ET AL., BAD BUGS, NO DRUGS: NO ESKAPE! AN UPDATE FROM THE
INFECTIOUS DISEASES SOCIETY OF AMERICA 2 (2009), available at http://www.idsociety.org
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The Second Circuit in NRDC v. FDA sought to address some of
these health concerns after the safety of two antibiotics used subthera-
peutically in livestock feed were found by the FDA to be questionable.159
However, despite nearly four decades of inaction by the FDA and compel-
ling arguments that FDA action is statutorily mandated, the Second
Circuit chose to defer to the FDA’s decision to refuse to investigate these
concerns.160 This decision allows the FDA to indefinitely refuse to address
serious health concerns, and undermines attempts to reduce growing
rates of antimicrobial drug resistance.161
Although several recent legislative attempts to curb the overuse of
antibiotics have failed, President Obama issued an Executive Order that
will hopefully spark increased efforts.162 The September 2014 National
Strategy on Combating Antimicrobial Drug Resistance is a crucial step
to prioritize the concern of antimicrobial drug resistance, strengthen
surveillance and collaboration, and advance research and development
regarding bacterial threats.163
However, the National Strategy does not specifically address ways
to deal with the agricultural overuse of antibiotics, which is where the
majority of medically unnecessary drugs get introduced into organisms
and the environment.164
Effective management of resistance will require sweeping agricul-
tural reforms and scientific research directed towards improving farming
methods. A greater focus on scientific research to develop cost-effective
vaccines for livestock, healthier nutrition plans to curb the necessity for
drugs, and alternative feed additives are fundamental first steps towards
enabling industry to reduce reliance on antibiotics in feed.
Furthermore, we should look towards Europe and other interna-
tional strategies that have been used to deal with the threat of antibiotic
resistance. Europe generally has stricter agricultural and antibiotic usage
laws, and some countries have experimented with different policies.165
The National Strategy should consider the European Commission’s
Action plan166 for ways to improve from a regulatory and policymaking
standpoint. The United States should also look towards Denmark and its
159 Winters, supra note 104.
160 Id.
161 Id.
162 See supra Part IV.
163 Id.
164 Id.
165 Levy, supra note 129.
166 Id.
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success in curbing the rates of several strains of resistant bacteria after
implementing a ban on the use of avoparcin in pork.167 Implementing a
similar restriction or ban has the potential to also curb resistance with-
out harming economic production and efficiency.
Addressing antibiotic resistance in the United States and raising
public awareness is vital to protecting public health and our environment.
While tackling this goal will inevitably require time and resources, it is
necessary to prevent the more costly possibilities of widespread diseases,
greater infections, and lack of effective medicines. Reforming the agricul-
tural industry is feasible, realistic, and would have the greatest impact on
reducing the rates of antimicrobial resistance. Policymakers, industry, and
scientific research institutions must all develop strategies aimed at ad-
dressing agricultural practices. Only then will the threat of antimicrobial
drug resistance be reduced to a manageable level.
167 Id.

